Yahoo
OTC Markets OTCQB - Delayed Quote USD

CERo Therapeutics Holdings, Inc. (CERO)

0.0040 -0.0010 (-20.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for CERO
  • Previous Close 0.0050
  • Open 0.0045
  • Bid 0.0032 x 34925100
  • Ask 0.0040 x 3921700
  • Day's Range 0.0032 - 0.0045
  • 52 Week Range 0.0030 - 0.2090
  • Volume 535,723
  • Avg. Volume 629,850
  • Market Cap (intraday) 286,523
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 40.3400
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

www.cero.bio

8

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CERO
94.03%
S&P 500 (^GSPC)
10.73%

1-Year Return

CERO
95.79%
S&P 500 (^GSPC)
11.11%

3-Year Return

CERO
100.00%
S&P 500 (^GSPC)
81.91%

5-Year Return

CERO
100.00%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -48.45M
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-30M
-20M
-10M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -279.03%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -95.3M

  • Diluted EPS (ttm)

    40.3400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    862.76k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    4.01M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: